These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 14734600)
41. [A combination of antianginal agents in patients with angina pectoris]. Kokurina EV; Kukushkin SK Kardiologiia; 1991 Sep; 31(9):80-4. PubMed ID: 1684398 [No Abstract] [Full Text] [Related]
42. Ranolazine: a potential new treatment for chronic stable angina. Anderson JR; Khou S; Nawarskas JJ Heart Dis; 2001; 3(4):263-9. PubMed ID: 11975803 [TBL] [Abstract][Full Text] [Related]
43. Ranolazine for the management of coronary artery disease. Cheng JW Clin Ther; 2006 Dec; 28(12):1996-2007. PubMed ID: 17296457 [TBL] [Abstract][Full Text] [Related]
44. [Drugs acting on the heart in therapy of silent myocardial ischemia]. Motz W; Scheler S; Strauer BE Internist (Berl); 1992 Oct; 33(10):695-700. PubMed ID: 1358855 [No Abstract] [Full Text] [Related]
45. Pharmacologic Treatment of Patients With Myocardial Ischemia With No Obstructive Coronary Artery Disease. Turgeon RD; Pearson GJ; Graham MM Am J Cardiol; 2018 Apr; 121(7):888-895. PubMed ID: 29394999 [TBL] [Abstract][Full Text] [Related]
46. [Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. Results of CARISA]. Gratsianskiĭ NA Kardiologiia; 2004; 44(3):78. PubMed ID: 15489836 [No Abstract] [Full Text] [Related]
50. Ranolazine (Ranexa) in the treatment of chronic stable angina. Aslam S; Gray D Adv Ther; 2010 Apr; 27(4):193-201. PubMed ID: 20449698 [TBL] [Abstract][Full Text] [Related]
51. Pharmacological and emerging therapies in the treatment of chronic angina. Husted SE; Ohman EM Lancet; 2015 Aug; 386(9994):691-701. PubMed ID: 26334161 [TBL] [Abstract][Full Text] [Related]
52. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Rupp H; Zarain-Herzberg A; Maisch B Herz; 2002 Nov; 27(7):621-36. PubMed ID: 12439634 [TBL] [Abstract][Full Text] [Related]
53. Ranolazine: an antianginal drug with antiarrhythmic properties. Tamargo J; Caballero R; Delpón E Expert Rev Cardiovasc Ther; 2011 Jul; 9(7):815-27. PubMed ID: 21809962 [TBL] [Abstract][Full Text] [Related]
54. Ranolazine: augmenting the antianginal armamentarium. Cairns JA J Am Coll Cardiol; 2006 Aug; 48(3):576-8. PubMed ID: 16875986 [No Abstract] [Full Text] [Related]
55. Effects of ranolazine on cardiovascular system. Bonadei I; Vizzardi E; Quinzani F; Piovanelli B; Rovetta R; D'Aloia A; Cas LD Recent Pat Cardiovasc Drug Discov; 2011 Sep; 6(3):215-21. PubMed ID: 21867482 [TBL] [Abstract][Full Text] [Related]
56. Extended-release ranolazine: critical evaluation of its use in stable angina. Truffa AA; Newby LK; Melloni C Vasc Health Risk Manag; 2011; 7():535-9. PubMed ID: 21915171 [TBL] [Abstract][Full Text] [Related]
57. Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain. Hidalgo-Vega A; Ramos-Goñi JM; Villoro R Eur J Health Econ; 2014 Dec; 15(9):917-25. PubMed ID: 24122303 [TBL] [Abstract][Full Text] [Related]
58. Medical therapy after successful percutaneous coronary revascularization. Hasdai D; Lerman A; Grill DE; Rihal CS; Holmes DR Ann Intern Med; 1999 Jan; 130(2):108-15. PubMed ID: 10068356 [TBL] [Abstract][Full Text] [Related]
60. Costs and clinical outcomes associated with use of ranolazine for treatment of angina. Phelps CE; Buysman EK; Gomez Rey G Clin Ther; 2012 Jun; 34(6):1395-1407.e4. PubMed ID: 22608105 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]